F.D.A.’s Approval of a Drug for Autism Upends Review Processnews2025-09-23T23:09:46+00:00September 23rd, 2025|The New York Times|
Harvard Dean Was Paid $150,000 as an Expert Witness in Tylenol Lawsuitsnews2025-09-23T21:57:24+00:00September 23rd, 2025|The New York Times|
4 Autism Experts React to Trump’s Plannews2025-09-23T18:50:52+00:00September 23rd, 2025|The New York Times|
Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisisnews2025-09-23T04:39:03+00:00September 23rd, 2025|The New York Times|
La empresa detrás de Tylenol intenta sortear su crisis más recientenews2025-09-23T04:01:05+00:00September 23rd, 2025|The New York Times|
These Patients Got the Cure. Then It Went Away.news2025-09-22T22:35:25+00:00September 22nd, 2025|The New York Times|
Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growthnews2025-09-22T04:01:17+00:00September 22nd, 2025|The New York Times|
FDA OKs New Keytruda Shot for Cancernews2025-09-19T20:43:52+00:00September 19th, 2025|The New York Times|
America’s Vaccine Future Is at a Crossroadsnews2025-09-19T20:33:33+00:00September 19th, 2025|The New York Times|
FDA Director Marty Makary: I’m Cracking Down on Pharma Adsnews2025-09-13T11:00:03+00:00September 13th, 2025|The New York Times|
